Ivermectin Resources
Recently, I have seen tremendous demand for some sort of initial guidance “WHERE TO START” with High Dose Ivermectin for CANCER.
.png "ivermectin dosage for cancer") |
| Updated version |
I have an article and a video that go into depth:
2025 studies on ivermectin for cancer
- Yuan Yuan et al (Cedars-Sinai Medical Center) – A phase I/II study evaluating the safety and efficacy of ivermectin in combination with balstilimab in patients with metastatic triple negative breast cancer (ASCO 2025)
- Yuwen et al – A Review of Ivermectin Use in Cancer Patients: Is it Time to Repurpose the Ivermectin in Cancer Treatment?
- Morinaga et al – Ivermectin Combined With Recombinant Methioninase (rMETase) Synergistically Eradicates MiaPaCa-2 Pancreatic Cancer Cells.
2024 studies
2024 Baghli et al – Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment: A Hybrid Orthomolecular Protocol
First-in-the-World Ivermectin, Mebendazole and Fenbendazole Protocol in Cancer has been peer-reviewed and published on Sep.19, 2024. Co-authors include Dr Paul Marik and Dr William Makis.
(2024 Kaur et al) – Ivermectin: A Multifaceted drug with a potential beyond anti-parasitic therapy
(2024 Xing Hu et al) – Ivermectin as a potential therapeutic strategy for glioma
(2024 Yang Song et al) – Gene signatures to therapeutics: Assessing the potential of ivermectin against t(4;14) multiple myeloma
(2024 Goldfarb et al) – Lipid-Restricted Culture Media Reveal Unexpected Cancer Cell Sensitivities
(2024 Newell et al) – Therapeutic targeting of nuclear export and import receptors in cancer and their potential in combination chemotherapy
Oct. 2, 2023 – IVERMECTIN and CANCER, it has at least 15 anti-cancer mechanisms of action. Can Ivermectin Treat COVID-19 mRNA Vaccine Induced Turbo Cancers? – 9 Ivermectin papers reviewed
IVERMECTIN and CANCER RESEARCH:
Top 5 Turbo Cancers are: Lymphoma, Glioblastoma, Breast, Colon, Lung Cancer.
IVERMECTIN could help with aggressive cancer or Turbo Cancer, or regular cancers.
Here are recent studies on IVERMECTIN use in certain types of cancer:
BLADDER CANCER – (2024 Fan et al) – Ivermectin Inhibits Bladder Cancer Cell Growth and Induces Oxidative Stress and DNA Damage
LUNG CANCER – (2024 Man-Yuan Li et al) – Ivermectin induces nonprotective autophagy by downregulating PAK1 and apoptosis in lung adenocarcinoma cells
GLIOMA – (2024 Xing Hu et al) – Ivermectin as a potential therapeutic strategy for glioma
MULTIPLE MYELOMA – (2024 Yang Song et al) – Gene signatures to therapeutics: Assessing the potential of ivermectin against t(4;14) multiple myeloma
OVARIAN CANCER – (2023 Jawad et al) – Ivermectin augments the anti-cancer activity of pitavastatin in ovarian cancer cells
PROSTATE CANCER – (2022 Lu et al) – Integrated analysis reveals FOXA1 and Ku70/Ku80 as targets of ivermectin in prostate cancer
COLON CANCER – (2022, Alghamdi et al) – Efficacy of ivermectin against colon cancer induced by dimethylhydrazine in male wistar rats
PANCREATIC CANCER – (2022 Lee et al) – Ivermectin and gemcitabine combination treatment induces apoptosis of pancreatic cancer cells via mitochondrial dysfunction
MELANOMA – (2022 Zhang et al) – Drug repurposing of ivermectin abrogates neutrophil extracellular traps and prevents melanoma metastasis
CERVICAL CANCER – (2022, Qabbus et al) – Ivermectin-induced cell death of cervical cancer cells in vitro a consequence of precipitate formation in culture media
HEPATOCELLULAR CARCINOMA – (2022 Lu et al) – Ivermectin synergizes sorafenib in hepatocellular carcinoma via targeting multiple oncogenic pathways
OSTEOSARCOMA – (2022 Hu et al) – Repurposing Ivermectin to augment chemotherapy’s efficacy in osteosarcoma
GASTRIC CANCER – (2021 Rabben et al) – Computational drug repositioning and experimental validation of ivermectin in treatment of gastric cancer
LEUKEMIA – (2020, de Castro et al) – Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infection
ESOPHAGEAL SCC – (2020, Chen et al) – Ivermectin suppresses tumour growth and metastasis through degradation of PAK1 in oesophageal squamous cell carcinoma
CHOLANGIOCARCINOMA – (2019 Intyuod et al) – Anti-parasitic drug ivermectin exhibits potent anticancer activity against gemcitabine-resistant cholangiocarcinoma in vitro
BREAST CANCER STEM CELLS – (2018 Dominguez-Gomez et al) – Ivermectin as an inhibitor of cancer stem-like cells.
CML (CHRONIC MYELOID LEUKEMIA) – (2018 Wang et al) – Antibiotic ivermectin selectively induces apoptosis in chronic myeloid leukemia through inducing mitochondrial dysfunction and oxidative stress.
RENAL CELL CARCINOMA – (2017 Zhu et al) – Antibiotic ivermectin preferentially targets renal cancer through inducing mitochondrial dysfunction and oxidative damage
GLIOBLASTOMA – (2016 Liu et al) – Anthelmintic drug ivermectin inhibits angiogenesis, growth and survival of glioblastoma through inducing mitochondrial dysfunction and oxidative stress.
Ivermectin Anti-Cancer Mechanisms of Action
IVERMECTIN has proven anti-cancer activity against some 20 cancer types, although these are pre-clinical studies. We will never see clinical studies because Ivermectin is off patent and cheap.
Merck, which used to have a patent on Ivermectin, has partnered with Moderna on mRNA Cancer Vaccines, estimated to cost 400,000 GBP per treatment.
Ivermectin studies on mice include: Breast cancer, Colon cancer, glioblastoma, glioma and leukemia.
I have not seen IVERMECTIN studies on Lymphoma, Testicular Cancer, Sarcomas.
IVERMECTIN acts on Cancer mainly by inhibiting signaling pathways involved in cancer proliferation (Akt, Wnt, mTOR) and by inhibiting CANCER STEM CELLS.
IVERMECTIN ACCESS
The Ontario College of Physicians even had an Investigator go undercover and dress up as a Canadian Trucker to ensnare a young doctor prescribing Ivermectin in Ottawa in 2022 during the Trucker Convoy.
Canadians must realize that the Colleges of Physicians are private corporations, fully bought off by big pharma and run by mafia lawyers like Bryan Salte (the SK lawyer who issued the $44,800 penalty for prescribing Ivermectin) – see below:
No healthcare bureaucrat or lawyer has the right to deny anyone access to life saving medication. And if they do, they are committing a very serious crime.
New & Improved Joe Tippens Protocol
- Fenbendazole is commonly taken at 300 mg for six days a week, with doses increasing to up to 1 gram in cases of aggressive “turbo cancers”. The original Joe Tippens protocol recommended the Panacur C brand of fenbendazole.
- Ivermectin (24 mg, 7 days a week) or in the case of severe turbo cancers up to 1mg/kg/day.
- Bio-Available Curcumin (600mg per day, 7 days a week).
- Vitamin D (62.5 mcg [2500 IU] seven days a week).
- Enhanced absorption Berberine (500mg per day) if you are trying to starve your cancer of sugars.
- Diet and Lifestyle: Removing sugar from one’s diet is crucial during this protocol (BMJ 2023), eating a nutritious fresh whole-food diet with fruits and vegetables, avoid ultra processed foods (BMJ 2024) and a healthy lifestyle with less stress.
- CBD oil (1-2 droppers full [equal to 167 to 334 mg per day] under the tongue, 7 days a week).
“I have eliminated Vitamin E as a required part of the protocol as there are simply too many instances (eg, blood thinners) where it needs to be eliminated, and it is the least important of the items.”
Fenbendazole
New Studies since last Article
- (2024 Apr, Rodrigues et al) – Repurposing mebendazole against triple-negative breast cancer CNS metastasis
- (2024 Feb, Eid et al) – Investigating the Promising Anticancer Activity of Cetuximab and Fenbendazole Combination as Dual CBS and VEGFR-2 Inhibitors and Endowed with Apoptotic Potential
- (2024 Feb, Park et al) – The microtubule cytoskeleton: A validated target for the development of 2-Aryl-1H-benzo[d]imidazole derivatives as potential anticancer agents
- (2024 Jan, Matsuo et al) – Parbendazole as a promising drug for inducing differentiation of acute myeloid leukemia cells with various subtypes
- (2023, Dec, Iragavarapu-Charyulu et al) – A novel treatment to enhance survival for end stage triple negative breast cancer using repurposed veterinary anthelmintics combined with gut‑supporting/immune enhancing molecules
- (2023 Nov, Aliabadi et al) – In vitro and in vivo anticancer activity of mebendazole in colon cancer: a promising drug repositioning
- (2023 Nov, Jung et al) – Fenbendazole Exhibits Differential Anticancer Effects In Vitro and In Vivo in Models of Mouse Lymphoma
- (2023 Sep, Garg et al) – Network pharmacology and molecular docking study-based approach to explore mechanism of benzimidazole-based anthelmintics for the treatment of lung cancer
- (2023 Jun, Mukherjee et al) – Ketogenic diet as a metabolic vehicle for enhancing the therapeutic efficacy of mebendazole and devimistat in preclinical pediatric glioma
- (2023 Feb, Lee et al) – Benzimidazole and its derivatives as cancer therapeutics: The potential role from traditional to precision medicine
Benzimidazole family and Cancer
There is still some research being done on Fenbendazole & Cancer, but researchers are focusing more on other related compounds in the “Benzimidazole family”, namely Mebendazole, but also Albendazole, Parbendazole. Why?
Benzimidazole Cost: Fenbendazole vs Mebendazole vs Albendazole
Fenbendazole is not FDA approved. It’s dirt cheap.
Mebendazole is FDA approved. It’s expensive. Check out “Fenbendazole vs Mebendazole for Cancer“.
PRACTICAL APPROACH TO USING FENBENDAZOLE IN CANCER TREATMENT (Disclaimer: the following is not medical advice)
The 10 new studies published in 2023-2024 only confirm what we already know from previous studies. Fenbendazole, Mebendazole, Albendazole are highly effective against many cancers.
There is one article I want to highlight though because it has an extremely important concept:
- 2023 Jun, Mukherjee et al – Ketogenic diet as a metabolic vehicle for enhancing the therapeutic efficacy of mebendazole and devimistat in preclinical pediatric glioma
- “This study investigated the influence of nutritional ketosis on the therapeutic action of mebendazole (MBZ) and devimistat (CPI-613) against the highly invasive VM-M3 glioblastoma cells in juvenile syngeneic p20-p25 mice”
- “maximum therapeutic benefit of mebendazole and CPI-613 on tumour invasion and mouse survival occurred only when the drugs were administered together with a ketogenic diet (KD)
KETOGENIC DIET IS CRUCIAL IN CANCER
Since my previous Fenbendazole article, I‘ve had 1000s of questions sent to me. Not about mechanisms of action against Cancer. But about practical use – how to use Fenbendazole or Mebendazole to treat Stage 4 Cancers, what formulations, what doses?
The goal of this article (Part 2) is to answer many of those questions to the best of my ability.
EXPERIMENTAL CANCER PROTOCOLS:
- You can look at fenbendazole.org for suggested dosing and dose calculator
- Dr.Tom Rogers, Founder of “Performance Medicine” has similar protocols.
- For anyone COVID-19 mRNA Vaccinated diagnosed with cancer (Turbo Cancer), I’d probably be looking at starting at 444 mg a day.
- For particularly aggressive Turbo Cancers or bad cases, I’d even consider pushing towards 888 mg/day (444 mg twice a day) or 1000 mg/day.
- Highest dosing I’ve seen is 30-50mg/kg/day for 5 days, based on the “Merck Manual”, however very few claim to have taken this dose.
- Fenbendazole can elevate liver function tests, so it would be a good idea to have a family doctor monitor those
Mebendazole: Key Resources
So far, several studies in the literature have used 200mg/day with some success, however given that it is safe to go up to 4g/day, when we’re dealing with aggressive mRNA Induced Turbo Cancers, 200mg/day is probably not sufficient.
- 2021 Mansoori et al – For Maximum dose of 4g/day being safe, that’s from a Phase 2 Clinical Trial for Gastrointestinal Cancer
- 2021 Chai et al – summarizes the various studies that have looked at Mebendazole in Cancer and the doses used.
- 500 mg-1500 mg/day (Phase 1 Clinical Trial, pediatric brain tumors)
- 200 mg/day (2011 Dobrosotskaya et al) (adrenocortical ca)
- 200 mg/day (2014 Nygren et al) (colon ca lung and LN mets)
- 100 mg/day (Clinical Trial, UK)
- 800 mg three times a day (phase 2 clinical trial for patients with recurrent glioblastoma) (2022 Patil et al).
- 2021 Chai et al – Albendazole vs fenbendazole for cancer? Why Mebendazole over Albendazole: “However, because of the toxicity of albendazole, for example, neutropenia due to myelosuppression, if high doses are used for a prolonged time, mebendazole is currently more popularly used than albendazole in anti-cancer clinical trials.”
- 2022 Joe et al – As a review, using a variety of in-vitro (petri dish) and in-vivo (live animal) models, Joe et al showed that mebendazole prevented the development of triple-negative breast cancer and eradicated previously established triple-negative breast cancer, and also reduced distant lung metastasis while preventing liver metastasis. Furthermore, mebendazole treatment led to a dramatic reduction in the cellular marker, Integrin β4 (ITGβ4), which is linked to the development of Cancer Stem Cells in distant locations. Even though these data were primarily animal data they would likely be applicable to humans.
- 2003 Chen et al – Precaution: Importantly, a combined use of mebendazole (>500 mg) and metronidazole (>500 mg) is prohibited because severe and rare fatal adverse events such as Stevens-Johnson syndrome (or toxic epidermal necrosis) may occur. The risk increased with increasing doses of metronidazole but not mebendazole, and there may be a synergistic interaction between mebendazole and metronidazole.
